These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11236608)

  • 41. Antibacterial therapy--special considerations in neutropenic patients.
    Rodriguez V; Bodey GP
    Clin Haematol; 1976 Jun; 5(2):347-60. PubMed ID: 181192
    [No Abstract]   [Full Text] [Related]  

  • 42. Is there a role for monotherapy with beta-lactam antibiotics in the initial empirical management of febrile neutropenic cancer patients?
    Hathorn JW; Pizzo PA
    J Antimicrob Chemother; 1986 Mar; 17 Suppl A():41-54. PubMed ID: 3519563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of glycopeptide antibiotics in the treatment of febrile neutropenic patients.
    Smith SR; Cheesbrough J; Harding I; Davies JM
    Br J Haematol; 1990 Dec; 76 Suppl 2():54-6. PubMed ID: 2149054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management in the febrile, neutropenic patient with cancer: therapeutic considerations.
    Brown AE
    J Pediatr; 1985 Jun; 106(6):1035-42. PubMed ID: 3889253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of imipenem as empirical treatment of febrile neutropenia.
    Klastersky JA
    Int J Antimicrob Agents; 2003 May; 21(5):393-402. PubMed ID: 12727070
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized case-controlled study of recombinant human granulocyte colony stimulating factor for the treatment of sepsis in preterm neutropenic infants.
    Aktaş D; Demirel B; Gürsoy T; Ovalı F
    Pediatr Neonatol; 2015 Jun; 56(3):171-5. PubMed ID: 25458637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone.
    Suwangool P; Aswapokee N; Sathapatayavongs B; Leelasuphasri S; Siritanaratkul N; Chuncharunee S; Chayakul P
    J Med Assoc Thai; 1993 Jun; 76(6):314-8. PubMed ID: 8083623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Bacterial sepsis in the hematologic neutropenic patient].
    Todeschini G; Benato G; Carlini S; Veneri D
    Haematologica; 1989 Oct; 74(5 Suppl):297-309. PubMed ID: 2480272
    [No Abstract]   [Full Text] [Related]  

  • 51. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation.
    Egerer G; Goldschmidt H; Salwender H; Hegenbart U; Ehrhard I; Haas R; Ho AD
    Int J Antimicrob Agents; 2000 Jul; 15(2):119-23. PubMed ID: 10854807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Empirical antibiotics for febrile neutropenic cancer patients.
    Hathorn JW
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S43-51. PubMed ID: 2693109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initial empirical antimicrobial therapy: duration and subsequent modifications.
    Tamura K
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S59-64. PubMed ID: 15250024
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia.
    Koh A; Pizzo PA
    Cancer Invest; 2002; 20(3):420-33. PubMed ID: 12025236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outpatient antibiotic therapy in febrile neutropenic patients undergoing high-dose chemotherapy and autologous bone marrow support.
    Rubenstein EB; Rolston K; Elting L
    J Clin Oncol; 1994 Nov; 12(11):2516-7. PubMed ID: 7964970
    [No Abstract]   [Full Text] [Related]  

  • 57. Management of the febrile neutropenic patient: a consensus conference.
    Picazo JJ
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S1-6. PubMed ID: 15250013
    [No Abstract]   [Full Text] [Related]  

  • 58. Expanding the options for risk-based therapy in febrile neutropenia.
    Rolston KV
    Diagn Microbiol Infect Dis; 1998 Jun; 31(2):411-6. PubMed ID: 9635917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tobramycin-cephalothin treatment in leukaemic and neutropenic patients with severe infection.
    Papayannis AG; Thomopoulos D; Voulgaris E; Scliros P; Gardikas C
    J Antimicrob Chemother; 1977 Jul; 3(4):311-5. PubMed ID: 893240
    [No Abstract]   [Full Text] [Related]  

  • 60. Economic issues: toward a cost-effective approach to the management of febrile neutropenia in Japan.
    Masaoka T
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S68-9. PubMed ID: 15250026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.